Repeat transurethral resection of bladder tumor (re‐TURBT) is commonly recommended for patients with non–muscle‐invasive bladder cancer (NMIBC) with high‐risk features, although many individuals may undergo unnecessary procedures that increase morbidity without clear benefit. Urinary tumor DNA (utDNA) has emerged as a promising biomarker, and we evaluated the performance of a multidimensional utDNA assay (utLIFE) in this context. In a retrospective cohort of 161 patients who underwent re‐TURBT between May 2020 and May 2025, urine samples collected 2–6 weeks after initial TURBT were analyzed using utLIFE, which integrates shallow whole‐genome sequencing and targeted sequencing of 155 genes with machine learning–based classification. Residual tumor was identified in 35% of patients, and utLIFE demonstrated high diagnostic accuracy, with sensitivity of 80.7%, specificity of 96.2%, and overall accuracy of 90.7%, markedly outperforming urine cytology. A positive utLIFE result was the strongest independent predictor of residual disease (OR = 77.5, 95% CI: 22.4–268.2, p < 0.001). During a median follow‐up of 32.5 months, recurrence occurred in 20.5% of patients; recurrence was defined as urothelial tumor relapse within the urinary tract and did not include distant metastasis. utLIFE positivity was significantly associated with shorter recurrence‐free survival (HR = 16.4, 95% CI: 2.7–101.8, p = 0.003). Longitudinal testing further revealed that utDNA positivity frequently preceded cystoscopic evidence of recurrence by several months. These findings highlight the strong diagnostic and prognostic value of utDNA in identifying residual disease and predicting recurrence, supporting its potential role in refining postoperative management strategies for NMIBC.
To explore the feasibility and efficacy of the modified technique of totally intracorporeal ileal conduit (IC) construction via vaginal approach following robot-assisted radical cystectomy (RARC) in females. By comparing the perioperative outcomes of the modified technique with extracorporeal urinary diversion (ECUD), 31 females treated for bladder cancer with RARC and IC from May 2020 to December 2023 were retrospectively analyzed and divided into two groups: the ECUD group (10 patients) and the modified intracorporeal urinary diversion (MICUD group) (21 patients). The modified technique involved performing transvaginal natural orifice specimen extraction surgery (TV-NOSES) after RARC; followed by the transvaginal placement of an Endo-GIA stapler to manipulate the bowel for intracorporeal IC construction. Both groups’ surgeries were successfully completed by the same surgeon and team. Patients in the MICUD group had shorter total operative time, lower postoperative pain scores, quicker recovery, and shorter hospital stays. The learning curve of the MICUD showed two phases: a learning phase (cases 1-7) and a proficiency phase (cases 8-21). The incidence of postoperative complications between the two groups was similar. The mean follow-up times were 29.3 months (ECUD group) and 22.6 months (MICUD group). In the MICUD group, there was one case of local tumor recurrence, two cases of distant metastasis, including one death from progression; in the ECUD group, one patient had distant metastasis and died from progression. RARC with MICUD represents a safe, feasible and easy-to-learn minimally invasive surgical approach. Patients experience less trauma and faster recoveries.
This multicenter, retrospective study evaluated the impact of pelvic lymph node dissection (PLND) on survival outcomes in non-muscle invasive bladder cancer (NMIBC) patients undergoing radical cystectomy (RC) and identified factors associated with upstaging. A total of 544 NMIBC patients who underwent RC with or without PLND between 2019 and 2024 were analyzed. Survival outcomes, including cancer-specific survival (CSS) and recurrence-free survival (RFS), were compared using Kaplan-Meier analysis and Cox proportional hazards models, while factors associated with upstaging were examined through logistic regression. Of the 544 patients, 509 (93.6%) were staged as cT1, and 412 (75.7%) underwent PLND. Upstaging occurred in 193 patients (35.5%), with pathological stages distributed as pT1 (50.0%), pT2 (20.8%), pT3 (11.2%), and pT4 (3.5%). Among patients who underwent PLND, 29 (7.0%) had positive lymph nodes. PLND was associated with improved RFS (5-year: 84.3% vs. 71.5%; adjusted hazard ratio [HR] = 0.33, 95% confidence interval [CI]: 0.20–0.56, p < 0.001) but did not significantly impact CSS (5-year: 86.5% vs. 81.6%; adjusted HR = 0.57, 95% CI: 0.32–1.02, p = 0.06). Lymph node positivity was linked to the worst prognosis. cT1 tumors, histological subtypes, and PLND were significant predictors of upstaging. In patients with cT1 tumors or histological subtypes, repeat transurethral resection is recommended to obtain more precise staging, which may inform further therapeutic decisions. While PLND is not routinely recommended for all NMIBC patients, it may be considered in those with high-risk features, particularly cT1 tumors or histological subtypes.
Objective: To explore if switching intravesical chemotherapeutic agents is beneficial in short-term recurrences of high-risk non-muscle-invasive bladder cancer (NMIBC) following the failure of preceding intravesical therapy. Materials and methods: From June 2010 to October 2015, 205 patients with NMIBC who experienced tumor recurrence within a year after receiving first-line intravesical chemotherapy (IVC) were classified into two groups. After a second complete transurethral resection (TUR) process, we immediately altered the intravesical instillation agent for 107 patients (group A). In contrast, the remaining 98 patients (group B) continued using their original intravesical instillation agent. After transurethral resection of the bladder tumor (TURBT), all patients received either an immediate instillation of epirubicin (EPI), gemcitabine (GEM), or hydroxycamptothecin (HCPT), followed by regular induction and maintenance instillations. Recurrence and progression rates were evaluated using the Chi-square test, and recurrence-free survival (RFS) and progression-free survival (PFS) were calculated using the Kaplan–Meier method. Results: In this study, there was no significant difference in either the 5-year tumor recurrence or progression rates between the two groups (p > 0.05) The Kaplan–Meier plot showed no difference in progression-free or recurrence-free survival between the two groups. Conclusion: Switching IVC agents does not improve RFS and PFS for patients with short-term recurrent high-risk NMIBC.
Objective: To assess whether switching intravesical chemotherapeutic agent is beneficial in short-term recurrent high-risk non-muscle-invasive bladder cancer (NMIBC) after failure of previous intravesical therapy. Materials and methods: From June 2010 to October 2015, 215 patients with NMIBC, who had tumor recurrence within one year of first-line drugs for Intravesical chemotherapy (IVC), were assigned to two groups. After a second time complete TUR treatment, we immediately changed the intravesical instillation agent for 107 patients (group A), whereas the other 98 patients continued to use their original intravesical instillation agent (group B - control group). All patients received an immediate instillation of epirubicin (EPI), gemcitabine (Gem) or hydroxycamptothecin (HCPT) after TURBT and followed by regularly induction plus maintenance instillations. Recurrence rate and progression rate were assessed by Chi-square test, while recurrence-free survival and progression-free survival were calculated using the Kaplan–Meier method. Results: In this study, the recurrence rate was 49.5% (53/107) in group A and 50.0% (49/98) in group B, while progression rate was 18.7% (21/107) in group A and 23.5% (23/98) in group B. Neither recurrence nor progression rates showed any significant differences between the two groups. Median progression interval between two groups were 24 months and 17 months, respectively (p=0.044). Average progression time between two groups were 28.7months and 19.3 months, respectively (p=0.035). In the Kaplan–Meier plot, no difference was found with respect to recurrence-free survival and progression-free survival. Moreover, univariate analysis suggested that only tumor grade could be an independent risk factor related to recurrence (HR = 0.632; 95% CI 0.425-0.942; p = 0.024), while the presence of carcinoma in situ may be an independent risk factor related to progression (HR=0.159; 95% CI 0.037-0.683; p=0.013). Conclusions: Switching IVC agent can significantly prolong time of progression in patients with short-term recurrent high-risk NMIBC who are unavailability or unsuitability for BCG instillation. Furthermore, the finding may provide a new basis for drug selection in combination IVC.